Guided Therapeutics (GTHP) Receivables - Net (2010 - 2025)

Guided Therapeutics (GTHP) has 16 years of Receivables - Net data on file, last reported at $4000.0 in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net rose 33.33% year-over-year to $4000.0; the trailing twelve-month figure through Dec 2025 stood at $4000.0 (up 33.33% YoY), and the FY2025 full-year result was $4000.0, up 33.33% from the prior year.
• Receivables - Net fell to $4000.0 in Q4 2025, from $6000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $165.0 million in Q1 2022 to a low of $2000.0 in Q1 2025.
• A 5-year average of $23.3 million and a median of $8942.0 in 2023 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net surged 130852.38% in 2022 and slumped 99.97% in 2023, its largest moves.
• Tracing GTHP's Receivables - Net over 5 years: stood at $126000.0 in 2021, then sank by 61.9% to $48000.0 in 2022, then tumbled by 85.42% to $7000.0 in 2023, then slumped by 57.14% to $3000.0 in 2024, then jumped by 33.33% to $4000.0 in 2025.
• Business Quant data shows GTHP's Receivables - Net at $4000.0 in Q4 2025, $6000.0 in Q3 2025, and $8000.0 in Q2 2025.